Trade Report: Today, Allergan PLC (AGN) PT Lowered to $299.00

Today, Allergan PLC (AGN) PT Lowered to $299.00

Allergan PLC (NYSE:AGN) had its target price lowered by Mizuho from $305.00 to $299.00 in a report issued on Tuesday morning. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently weighed in on AGN. Bank of America Corp. set a $294.00 target price on Allergan PLC and gave the stock a buy rating in a research note on Tuesday, September 20th. Piper Jaffray Cos. restated a hold rating and set a $236.00 target price on shares of Allergan PLC in a research note on Saturday, June 18th. Credit Suisse Group AG set a $322.00 target price on Allergan PLC and gave the stock a hold rating in a research note on Wednesday, August 3rd. Leerink Swann restated a buy rating on shares of Allergan PLC in a research note on Thursday, June 30th. Finally, Goldman Sachs Group Inc. restated a buy rating on shares of Allergan PLC in a research note on Monday, September 12th. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Allergan PLC currently has a consensus rating of Buy and an average target price of $302.23.

Allergan PLC (NYSE:AGN) opened at 227.55 on Tuesday. Allergan PLC has a one year low of $195.50 and a one year high of $322.68. The company has a market cap of $90.10 billion, a price-to-earnings ratio of 21.67 and a beta of 0.81. The stock has a 50 day moving average of $238.01 and a 200-day moving average of $238.04.

Allergan PLC (NYSE:AGN) last posted its earnings results on Monday, August 8th. The company reported $3.35 earnings per share for the quarter, topping the consensus estimate of $3.34 by $0.01. The firm earned $3.68 billion during the quarter, compared to analysts’ expectations of $4.10 billion. Allergan PLC had a return on equity of 7.67% and a net margin of 28.06%. The firm’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $4.41 earnings per share. On average, equities analysts predict that Allergan PLC will post $14.00 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Barnett & Company Inc. purchased a new stake in Allergan PLC during the first quarter worth approximately $111,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new stake in Allergan PLC during the second quarter worth approximately $125,000. Trust Co. of Vermont increased its stake in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the last quarter. Carroll Financial Associates Inc. increased its stake in Allergan PLC by 68.7% in the third quarter. Carroll Financial Associates Inc. now owns 555 shares of the company’s stock worth $127,000 after buying an additional 226 shares during the last quarter. Finally, Ropes Wealth Advisors LLC increased its stake in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares during the last quarter. Institutional investors own 85.20% of the company’s stock.

Allergan PLC Company Profile

Related posts

Leave a Comment